Scarica l'app Stockscreener
9.90
1.02%
0.10
Dopo l'orario di chiusura:
10.00
0.10
+1.01%
Precedente Chiudi:
$9.80
Aprire:
$10.55
Volume 24 ore:
4.73M
Relative Volume:
2.25
Capitalizzazione di mercato:
$1.28B
Reddito:
$8.40M
Utile/perdita netta:
$-237.42M
Rapporto P/E:
-5.1528
EPS:
-1.9213
Flusso di cassa netto:
$-377.03M
1 W Prestazione:
-12.85%
1M Prestazione:
-64.04%
6M Prestazione:
-64.77%
1 anno Prestazione:
+130.23%
Intervallo 1D:
$9.65
$10.55
Intervallo di 1 settimana:
$9.65
$11.60
Portata 52W:
$3.76
$31.35
Alumis Inc Stock (ALMS) Company Profile
Nome
Alumis Inc
Settore
Industria
Telefono
650-231-6625
Indirizzo
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
9.90 | 1.27B | 8.40M | -237.42M | -377.03M | -1.9213 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Iniziato | Raymond James | Strong Buy |
| 2026-02-25 | Iniziato | Stifel | Buy |
| 2026-01-21 | Iniziato | Chardan Capital Markets | Buy |
| 2025-07-25 | Iniziato | Wells Fargo | Overweight |
| 2025-06-10 | Ripresa | Guggenheim | Buy |
| 2025-01-30 | Iniziato | Oppenheimer | Outperform |
| 2024-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2024-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Iniziato | Guggenheim | Buy |
| 2024-07-23 | Iniziato | Leerink Partners | Outperform |
| 2024-07-23 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Alumis Inc Borsa (ALMS) Ultime notizie
Why is Alumis stock rallying today? By Investing.com - Investing.com India
Alumis Insider Bought Shares Worth $10,726,255, According to a Recent SEC Filing - marketscreener.com
Alumis at Cantor conference: psoriasis strength, lupus setback - Investing.com
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares - Investing.com Canada
Alumis at Cantor conference: psoriasis strength, lupus setback By Investing.com - Investing.com Canada
Alumis (NASDAQ: ALMS) director buys 986K shares, agrees to give back trade profit - Stock Titan
Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population - finance.yahoo.com
Alumis at Wells Fargo conference: lupus setback sharpens strategy By Investing.com - Investing.com Canada
ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff? - stocktwits.com
Price-Driven Insight from (ALMS) for Rule-Based Strategy - Stock Traders Daily
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven DiseasesSlideshow (NASDAQ:ALMS) 2026-09-04 - Seeking Alpha
Alumis to Participate in Upcoming September Investor Conferences - The Manila Times
Four public talks are planned for September. Alumis will stream them online. - Stock Titan
Apple, Tesla, Nvidia, Medtronic, Alumis, Robinhood, Fervo, and More Stocks That Explain Today's Market -- Barrons.com - moomoo.com
Is Alumis (ALMS) Overvalued After Its 121% One Year Return? - finance.yahoo.com
Alumis stock downgraded at Guggenheim (ALMS:NASDAQ) - Seeking Alpha
Why Alumis (ALMS) Is Down 56.2% After Mixed Phase 2b Lupus Data Spotlight Biomarker Strategy - finance.yahoo.com
Guggenheim Downgrades Alumis to Neutral From Buy - marketscreener.com
Alumis (ALMS) Looks Pricey After Its Lupus Trial Miss But Is 3x P B Fair? - finance.yahoo.com
Alumis (ALMS) Lead Lupus Drug Missed Phase 2b Trial Endpoints - finance.yahoo.com
Guggenheim downgrades Alumis stock rating after trial miss By Investing.com - Investing.com Canada
Guggenheim downgrades Alumis stock rating after trial miss - Investing.com
Morgan Stanley cuts Alumis stock price target on lupus trial failure By Investing.com - Investing.com South Africa
Alumis (ALMS) Stock Slides As Momentum Traders Refocus On Fundamentals - timothysykes.com
Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says - marketscreener.com
This OGE Energy Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Oppenheimer Adjusts Price Target on Alumis to $37 From $55, Maintains Outperform Rating - marketscreener.com
Wells Fargo cuts Alumis stock price target on SLE trial results - Investing.com Australia
Morgan Stanley cuts Alumis stock price target on lupus trial failure - Investing.com
Wells Fargo cuts Alumis stock price target on SLE trial results By Investing.com - Investing.com South Africa
Alumis stock plunges 57% after lupus drug trial fails, but psoriasis drug progress continues. - Pluang
Alumis plunges 57% after trial failure; Enovis falls 16% on robotics acquisition news - Pluang
Alumis shares plunge after lupus trial failure, but drug potential remains uncertain - Pluang
Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside (NASDAQ:ALMS) - Seeking Alpha
Alumis Plunges 56% After Lupus Drug Fails Key Trial Goals - finance.biggo.com
Alumis’ TYK2 drug fails in key lupus study - BioPharma Dive
Alumis Shares Plummet 59% After Lupus Study Failure Wipes Out $1.67 Billion - TechStock²
Alumis stock tumbles 55% after lupus drug trial misses goals By Investing.com - Investing.com Nigeria
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise - TradingView
Why Is Alumis Stock Falling Tuesday? - Benzinga
Alumis Announces Topline Phase 2b Results for Envudeucitinib in Systemic Lupus Erythematosus - Kalkine Media
Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward' - Endpoints News
Alumis falls after trial setback for lead drug (ALMS:NASDAQ) - Seeking Alpha
Why is Alumis stock collapsing today? By Investing.com - Investing.com Australia
Alumis Phase 2b lupus trial misses primary and secondary endpoints - finance.yahoo.com
ALMS Stock Slides As Losses Mount Despite Strong Cash - StocksToTrade
Alumis stock tumbles 55% after lupus drug trial misses goals - Investing.com
Alumis Reports Mixed Phase 2b LUMUS Results for Envudeucitinib in SLE, Highlights IFNGS-High Subgroup and Safety Data - Quiver Quantitative
Alumis' lupus drug fails mid-stage trial goal - marketscreener.com
Trading Systems Reacting to (ALMS) Volatility - Stock Traders Daily
Alumis (NASDAQ:ALMS) Shares Down 7.9%What's Next? - MarketBeat
Alumis Inc Azioni (ALMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):